Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “outperform” rating reissued by Royal Bank of Canada in a research note issued on Tuesday, Benzinga reports. They presently have a $60.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 120.99% from the stock’s previous […]
Pacer Advisors Inc. decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 58.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,520 shares of the biotechnology company’s stock after selling 11,770 shares during the period. Pacer […]
TD Cowen assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report released on Friday morning, MarketBeat reports. The brokerage issued an outperform rating on the biotechnology company’s stock. Several other brokerages also recently issued reports on ARWR. B. Riley restated a buy rating and set a $55.00 price objective […]
TD Cowen assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report report published on Friday, Marketbeat Ratings reports. The firm issued an outperform rating on the biotechnology company’s stock. A number of other research firms also recently issued reports on ARWR. Sumitomo Mitsui Financial Group assumed coverage on shares […]
B. Riley reissued their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $55.00 price target on the biotechnology company’s stock. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at ($3.13) EPS. A number of other equities […]